Advertisement
News
Advertisement

Quanterix, Novartis sign biomarker deal

Tue, 02/22/2011 - 11:34pm
Mass High Tech: The Journal of New England Technology

Diagnostics company Quanterix Corp. today announced an evaluation agreement with Novartis Diagnostics under which the unit of Novartis AG will look at the potential use of Quanterix’s technology on a neuron-specific protein target.

Cambridge-based Quanterix offers a Single Molecule Array (SiMoA) technology for in vitro and life sciences research markets. The company claims that the digital nature of SiMoA offers a 1,000-fold improvement in sensitivity compared with analog-only technology.

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading